Introduction/Background Ovarian cancer is one of the leading causes of death in patients with gynecological malignancies. Despite therapeutic advances, ovarian cancer still spreads and relapses frequently with a poor prognosis. We aimed to study the association between the TGF-beta +915C/G polymorphism and clinicopathological parameters of ovarian cancer.

Methodology Genotyping of the TGF-beta +915C/G was performed using the Polymerase Chain Reaction-Sequence-Specific-Primer (PCR-SSP) technique. Clinicopathological parameters included age, tumor stage, and histological type. All statistical analyses were performed using the GraphPad Prism software.

Results The genetic analysis involved 30 patients with ovarian cancer and 35 control women. Gene polymorphism analysis of the TGF-beta revealed significant differences in genotype distribution between patients and controls. The frequency of the G allele in patients was higher in patients than in controls with a significant p-value (85% versus 15%; OR=6; 95% CI=[2.565–14.04]; p<0.0001). Additionally, the homozygous genotype (G/G) was significantly higher in patients than in controls (77% versus 31%). This later genotype (G/G) is significantly associated with the occurrence of the disease (OR=7.169; 95% CI=[2.284–21.06]; p=0.0003). Furthermore, we demonstrated that the G allele was significantly more represented in advanced-stages patients than in early-stages patients (94% versus 73%, OR=5.895, p=0.032).

Conclusion Our findings revealed a significant disparity in genotype distribution between ovarian cancer patients and controls, particularly highlighting the high frequency of the G allele in patients.

Disclosures The authors certify that there is no conflict of interest to declare.